Contrast-enhancing meningeal lesions are associated with longer survival in breast cancer-related leptomeningeal metastasis

Breast Care

Volumn 3, Issue 2, 2008, Pages 118-123

  Regierer, Anne Constanze ^a   Stroux, Andrea ^a   Kühnhardt, Dagmar ^a   Dieing, Annette ^a   Lehenbauer Dehm, Silvia ^a   Flath, Bernd ^b   Possinger, Kurt ^a   Eucker, Jan ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b H amatologisch Onkologische Praxis Altona   (Germany)

Author keywords

Breast cancer; Carcinomatous meningitis; Intrathecal chemotherapy; Leptomeningeal metastases; Neoplastic meningitis

Indexed keywords

ANTHRACYCLINE DERIVATIVE; AROMATASE INHIBITOR; CAPECITABINE; CYTARABINE; DEXAMETHASONE; HORMONE RECEPTOR; METHOTREXATE; NAVELBINE; TAXANE DERIVATIVE; THIOTEPA;

ADULT; AGED; AGRAPHIA; APHASIA; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARCINOMATOUS MENINGITIS; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DRUG WITHDRAWAL; GRAND MAL SEIZURE; HUMAN; MUCOSA INFLAMMATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA;

EID: 44949195823     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000121688     Document Type: Article

References (31)

1. Taillibert S, Laigle-Donadey F, Chodkiewicz C, Sanson M, Hoang-Xuan K, Delattre JY: Leptomeningeal metastases from solid malignancy: a review. J Neurooncol 2005;75(1):85-99.
2. Bokstein F, Lossos A, Siegal T: Leptomeningeal metastases from solid tumors: a comparison of two prospective series treated with and without intracerebrospinal fluid chemotherapy. Cancer 1998;82(9):1756-63.
3. Fizazi K, Asselain B, Vincent-Salomon A, Jouve M, Dieras V, Palangie T, Beuzeboc P, Dorval T, Pouillart P: Meningeal carcinomatosis in patients with breast carcinoma. Clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen. Cancer 1996;77(7):1315-23.
4. Boogerd W, Hart AA, van der Sande JJ, Engelsman E: Meningeal carcinomatosis in breast cancer. Prognostic factors and influence of treatment. Cancer 1991;67(6):1685-95.
5. Kerr JZ, Berg S, Blaney SM: Intrathecal chemotherapy. Crit Rev Oncol Hematol 2001;37(3):227-36.
6. Shapiro WR, Young DF, Mehta BM: Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 1975;293(4):161-6.
7. Siegal T, Sandbank U, Gabizon A, Mizrachi R, Ben-David E, Catane R: Alteration of blood-brain-CSF barrier in experimental meningeal carcinomatosis. A morphologic and adriamycin-penetration study. J Neurooncol 1987;4(3):233-42.
8. Ushio Y, Shimizu K, Aragaki Y, Arita N, Hayakawa T, Mogami H: Alteration of blood-CSF barrier by tumor invasion into the meninges. J Neurosurg 1981;55(3):445-9.
9. Freilich RJ, Krol G, DeAngelis LM: Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol 1995;38(1):51-7.
10. Sagar SM: Carcinomatous meningitis: it does not have to be a death sentence. Oncology (Williston Park) 2002;16(2):237-43; discussion 244, 249-50.
11. Stockhammer G, Poewe W, Burgstaller S, Deisenhammer F, Muigg A, Kiechl S, Schmutzhard E, Maier H, Felber S, Schumacher P, Gunsilius E, Gastl G: Vascular endothelial growth factor in CSF: a biological marker for carcinomatous meningitis. Neurology 2000;54(8):1670-6.
12. Reijneveld JC, Brandsma D, Boogerd W, Bonfrer JG, Kalmijn S, Voest EE, Geurts-Moespot A, Visser MC, Taphoorn MJ: CSF levels of angiogenesis-related proteins in patients with leptomeningeal metastases. Neurology 2005;65(7):1120-2.
13. van de Langerijt B, Gijtenbeek JM, de Reus HP, Sweep FC, Geurts-Moespot A, Hendriks JC, Kappelle AC, Verbeek MM: CSF levels of growth factors and plasminogen activators in leptomeningeal metastases. Neurology 2006;67(1):114-9.
14. Herrlinger U, Wiendl H, Renninger M, Forschler H, Dichgans J, Weller M: Vascular endothelial growth factor (VEGF) in leptomeningeal metastasis: diagnostic and prognostic value. Br J Cancer 2004;91(2):219-24.
15. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J: Vascular-specific growth factors and blood vessel formation. Nature 2000;407 (6801):242-8.
16. Blasberg RG, Patlak C, Fenstermacher JD: Intrathecal chemotherapy: brain tissue profiles after ventriculocisternal perfusion. J Pharmacol Exp Ther 1975;195(1):73-83.
17. Herrlinger U, Forschler H, Kuker W, Meyermann R, Bamberg M, Dichgans J, Weller M: Leptomeningeal metastasis: survival and prognostic factors in 155 patients. J Neurol Sci 2004;223(2): 167-78.
18. Boogerd W, van den Bent MJ, Koehler PJ, Heimans JJ, van der Sande JJ, Aaronson NK, Hart AA, Benraadt J, Vecht Ch J: The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study. Eur J Cancer 2004;40(18):2726-33.
19. Siegal T, Lossos A, Pfeffer MR: Leptomeningeal metastases: analysis of 31 patients with sustained off-therapy response following combined-modality therapy. Neurology 1994;44(8):1463-9.
20. Glantz MJ, Cole BF, Recht L, Akerley W, Mills P, Saris S, Hochberg F, Calabresi P, Egorin MJ: High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J Clin Oncol 1998;16(4): 1561-7.
21. Grant R, Naylor B, Greenberg HS, Junck L: Clinical outcome in aggressively treated meningeal carcinomatosis. Arch Neurol 1994;51(5):457-61.
22. Boogerd W, Dorresteijn LD, van der Sande JJ, de Gast GC, Bruning PF: Response of leptomeningeal metastases from breast cancer to hormonal therapy. Neurology 2000;55(1):117-9.
23. Ozdogan M, Samur M, Bozcuk HS, Sagtas E, Yildiz M, Artac M, Savas B: Durable remission of leptomeningeal metastasis of breast cancer with letrozole: a case report and implications of biomarkers on treatment selection. Jpn J Clin Oncol 2003;33 (5):229-31.
24. Rogers LR, Remer SE, Tejwani S: Durable response of breast cancer leptomeningeal metastasis to capecitabine monotherapy. Neuro Oncol 2004;6 (1):63-4.
25. Giglio P, Tremont-Lukats IW, Groves MD: Response of neoplastic meningitis from solid tumors to oral capecitabine. J Neurooncol 2003;65(2): 167-72.
26. Grossman SA, Finkelstein DM, Ruckdeschel JC, Trump DL, Moynihan T, Ettinger DS: Randomized prospective comparison of intraventricular metho-trexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. J Clin Oncol 1993;11(3):561-9.
27. Jayson GC, Howell A, Harris M, Morgenstern G, Chang J, Ryder WD: Carcinomatous meningitis in patients with breast cancer. An aggressive disease variant. Cancer 1994;74(12):3135-41.
28. Jaeckle KA, Phuphanich S, Bent MJ, Aiken R, Batchelor T, Campbell T, Fulton D, Gilbert M, Heros D, Rogers L, O'Day SJ, Akerley W, Allen J, Baidas S, Gertler SZ, Greenberg HS, LaFollette S, Lesser G, Mason W, Recht L, Wong E, Chamberlain MC, Cohn A, Glantz MJ, Gutheil JC, Maria B, Moots P, New P, Russell C, Shapiro W, Swinnen L, Howell SB: Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br J Cancer 2001;84(2): 157-63.
29. Siegal T: Toxicity of treatment for neoplastic meningitis. Curr Oncol Rep 2003;5(1):41-9.
30. Chamberlain MC, Kormanik PA, Barba D: Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. J Neurosurg 1997;87(5):694-9.
31. Balm M, Hammack J: Leptomeningeal carcinomatosis. Presenting features and prognostic factors. Arch Neurol 1996;53(7):626-32.